{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004927","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2024-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.066736+00:00","generated_at":"2026-06-04T00:29:03.279975+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aprea Therapeutics clears IND for APR-1051; updates on ATRN-119 Phase 1 at AACR","bullets":["IND for next-gen WEE1 inhibitor APR-1051 cleared; first patient dosing expected June 2024 in Phase 1 ACESOT-1051 trial.","ATRN-119 (ATR inhibitor) Phase 1/2a: enrolling 550 mg cohort; no DLTs, no Grade 4+ AEs; stable disease in two patients (one on treatment 188+ days).","Preclinical data show APR-1051 has >50-fold reduced PLK off-target inhibition vs ZN-c3; well tolerated with minimal hematotoxicity in mice.","New preclinical ATRN-333 combination with lomustine for glioblastoma shows synergy; intracranial delivery via convection-enhanced device."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004927","json":"https://secwatch.observer/filing/0001558370-24-004927.json","markdown":"https://secwatch.observer/filing/0001558370-24-004927.md","text":"https://secwatch.observer/filing/0001558370-24-004927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024004927/0001558370-24-004927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024004927/apre-20240410x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:29:03.279975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}